Iteos Therapeutics Inc

Iteos Therapeutics — Investor Presentation (January 2021)

16 slides from Iteos Therapeutics's investor presentation, Jan 11, 2021

  1. Slide 1: Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression

    Exhibit 99.1 Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression JANUARY 2021Exhibit 99.1 Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression JANUARY 2021

  2. Slide 2: Disclaimer

    Disclaimer This Presentation has been prepared by iTeos Therapeutics, Inc. (“we,” “us,” our “our”) and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are neither historical f

  3. Slide 3: iTeos Made Progress in 2020

    iTeos Made Progress in 2020 Building the Foundation to Support the Evolution of our Pipeline • Growing track record in immuno-oncology drug discovery and development relying on our deep expertise in the biology of the tumor microenvironment • Inupadenant (EOS-850),an A receptor antagonist, and EOS-4

  4. Slide 4: Pipeline of Promising Immuno-Oncology Product Candidates

    Pipeline of Promising Immuno-Oncology Product Candidates Program Trial Design Indications Preclinical Phase 1 Phase 1b/2a Phase 2/3 Initiation Data Adenosine A Receptor Antagonist 2A Expansion initiated Updated results 2Q Monotherapy Solid Tumors 2Q 2020 2021 Anti-PD-1-Resistant + pembrolizumab Init

  5. Slide 5: Inupadenant Potentially Best-in-Class Adenosine Receptor Antagonist

    Inupadenant Potentially Best-in-Class Adenosine Receptor Antagonist Phase 1/2 Program with Early Single Agent Activity 5Inupadenant Potentially Best-in-Class Adenosine Receptor Antagonist Phase 1/2 Program with Early Single Agent Activity 5

  6. Slide 6: Inupadenant: Designed to Overcome Immunosuppression in the Tumor Microenvironment

    Inupadenant: Designed to Overcome Immunosuppression in the Tumor Microenvironment iTeos scientists implemented rational drug design to overcome the shortcomings of other adenosine pathway drugs iTeos A Inupadenant Differentiation Others 2A Maintains potency in high adenosine Limited activity in the

  7. Slide 7: Inupadenant Monotherapy Demonstrated Preliminary Evidence of Clinical Benefit

    Inupadenant Monotherapy Demonstrated Preliminary Evidence of Clinical Benefit in Heavily Pretreated Patients Durable responses and target engagement observed in monotherapy dose escalation Inhibition of A R signaling 2A Test at 24h post-dose at 24h post-dose 40 mg QD 150 40 mg BID 80 mg BID 100 160

  8. Slide 8: Inupadenant Treatment Results: Confirmed PRs with Substantial Tumor Reduction

    Inupadenant Treatment Results: Confirmed PRs with Substantial Tumor Reduction CHECKPOINT INHIBITOR-REFRACTORY METASTATIC MELANOMA: HEAVILY PRE-TREATED mCRPC: è 44% tumor reductionè 49% tumor reduction è Patient reported decreased pain & improved mobilityè Patient reported decreased bone pain è Singl

  9. Slide 9: Inupadenant Phase 1/2 Clinical Plan: Rapidly Expanding in Several Tumor Types

    Inupadenant Phase 1/2 Clinical Plan: Rapidly Expanding in Several Tumor Types in Multiple Combinations Single Safety and PK/PD Signal-Seeking Agent Expansion Cohorts 2-Stage Expansions Inupadenant Single-agent Generation of additional data to Melanoma, CRPC, analyze the MoA and the specific CRPC (n=

  10. Slide 10: EOS-448 Anti-TIGIT Antibody Currently in Dose Escalation Phase 1/2 Trial

    EOS-448 Fc�� R-engaging Anti-TIGIT Antibody Currently in Dose Escalation Phase 1/2 Trial 10EOS-448 Fc�� R-engaging Anti-TIGIT Antibody Currently in Dose Escalation Phase 1/2 Trial 10

  11. Slide 11: EOS-448 is Designed to Enhance Anti-Tumor Immune Response

    EOS-448 is Designed to Enhance Anti-Tumor Immune Response Through T Cell Activation & FcgR Engagement Multiple programs have demonstrated that IgG1 antibodies are well tolerated at effective doses 3 Mechanisms of Action: Inhibition of TIGIT triggering activation Depletion of immunosuppressive Revers

  12. Slide 12: EOS-448's Ability to Block TIGIT is Associated with Superior Immune Activation

    EOS-448’s Ability to Block TIGIT is Associated with Superior Immune Activation EOS-448 is associated with enhanced IL-2 EOS-448 blocks binding of TIGIT to CD155 mediated gene expression EOS884448 EOS-448 4000 Mereo Mereo Genentech 3000 Genentech BMS Merck 2000 Merck BMS Arcus 1000 Arcus 0 -6 -4 -2 0

  13. Slide 13: FcgR Engagement Led to Preferential Depletion of Tregs

    FcgR Engagement Led to Preferential Depletion of Tregs, while Sparing Most Functional Effector T cells HIGH EOS-448 selectively depletes Tregs, sparing most TIGIT TILs have an exhausted phenotype LOW effector T cells compared to TIGIT TILs + + CD4 TIGIT+ CD8 TIGIT+ 100 IL-2 IFN�� TNF�� Fill 80 + + +

  14. Slide 14: EOS-448 Initial Clinical Plan: Biologically Driven

    EOS-448 Initial Clinical Plan: Biologically Driven with a Focus on Addressing Unmet Medical Needs Single Combination Agent POC Trials Rationale • Strong biological rationale • TIGIT upregulated on CD8+ T cells during progression EOS-448 + IMID • In vivo model suggests that TIGIT expression in post-t

  15. Slide 15: iTeos has Built the Foundation to Support Transformative Acceleration in 2021

    iTeos has Built the Foundation to Support Transformative Acceleration in 2021 Company well capitalized to fund aggressive growth in preclinical and clinical operations Significant data updates on both clinical programs in Q2 2021 Continue to progress Inupadenant ongoing monotherapy and combination s

  16. Slide 16: Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression

    Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression JANUARY 2021Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression JANUARY 2021

iTeos Therapeutics — Investor Presentation (January 2021) on 6ix